ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma cancer fda regulation

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Matthew Disney
A Quest to Drug RNA
Ida Emilie Steinmark, PhD | Sep 8, 2023 | 5 min read
Matthew Disney’s idea of small molecules that target RNA once seemed fanciful. Now, even the pharma industry is pursuing it
TS Picks: September 8, 2015
Jef Akst | Sep 8, 2015 | 1 min read
Pharma edition
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Pharma CPR
Brendan Borrell | Dec 1, 2009 | 7 min read
.table { font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; text-align: center; }.drug_table { font-size: 11px; font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; }.drug_table td { padding: 2px; border-left: 1px solid #CCCCCC; }.drug_table tr.even td, .drug_table thead tr td { font-weight: bold; }.drug_table thead tr td { font-size: 13px; color: #62A476; }.drug_table tr.even td { background: #F8E4B9; }.drug_table tr.odd td { bac
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018 | 2 min read
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Epigenetic Cancer Therapy Clears Phase I
Tracy Vence | Apr 7, 2014 | 2 min read
Investigational drug that inhibits proteins involved with epigenetic regulation shows activity against certain blood cancers in an early-stage clinical trial.

Run a Search

ADVERTISEMENT